Josh Hendy
Well-Known Member
For those of you interested in the malarial drug treatment for CV-19, the French doctors in Marseille have released the abstract of a much larger study. It is here: direct link to PDF.
The study had no control group so the crux of the matter is whether you believe this statement:
Mortality was significantly lower in patients who had received > 3 days of HCQ-AZ than in patients treated with other regimens ...
There are several other studies going on but so far virtually no other results are available, either final or preliminary.
1061 ... patients met our inclusion criteria. Their mean age was 43.6 years old ... No cardiac toxicity was observed. A good clinical outcome and virological cure was obtained in 973 patients within 10 days (91.7%). Prolonged viral carriage at completion of treatment was observed in 47 patients (4.4%) ... all but one were PCR-cleared at day 15. A poor outcome was observed for 46 patients (4.3%) ... 5 patients died (0.47%) (74-95 years old) ... Among this group, 25 patients are now cured and 16 are still hospitalized (98% of patients cured so far) ... Mortality was significantly lower in patients who had received > 3 days of HCQ-AZ than in patients treated with other regimens ... The HCQ-AZ combination, when started immediately after diagnosis, is a safe and efficient treatment for COVID-19, with a mortality rate of 0.5%, [mostly] in elderly patients. It avoids worsening and clears virus persistence and contagiosity in most cases.
The study had no control group so the crux of the matter is whether you believe this statement:
Mortality was significantly lower in patients who had received > 3 days of HCQ-AZ than in patients treated with other regimens ...
There are several other studies going on but so far virtually no other results are available, either final or preliminary.